{"name": "Alliqua",
 "permalink": "alliqua",
 "crunchbase_url": "http://www.crunchbase.com/company/alliqua",
 "homepage_url": "http://alliqua.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "646.218.1450",
 "description": "",
 "created_at": "Tue May 28 06:43:34 UTC 2013",
 "updated_at": "Tue May 28 06:44:49 UTC 2013",
 "overview": "\u003Cp\u003EHeadquartered in New York, Alliqua, Inc., (OTCBB:ALQA) is a biomedical company focused on the development, manufacturing and marketing of its own proprietary products, utilizing its existing technology portfolio. The company currently markets its own proprietary brands of wound dressings: SilverSeal\u00ae Hydrogel, an antimicrobial dressing; and Hydress\u00ae a moist wound dressing. We intend to pursue projects in the fields of active ingredient and transdermal drug delivery, as well as advanced wound care.\u003C/p\u003E\n\n\u003Cp\u003EAlliqua\u2019s core transdermal delivery technology platform is designed to deliver drugs and other beneficial ingredients through the skin.  Transdermal delivery has multiple advantages over conventional oral and injection delivery including:\u003C/p\u003E\n\n\u003Cpre\u003E\u003Ccode\u003EAvoidance of hepatic first pass metabolism causing less stress on the liver;\nNon-invasive nature;\nImproved patient compliance;\nDiscontinuation of administration by removal of the system;\nLower dosage;\nNo dependence on different metabolic rates of individuals; and\nNo interaction with the gastrointestinal system.\n\u003C/code\u003E\u003C/pre\u003E\n\n\u003Cp\u003EIn addition, Alliqua\u2019s patch technology can be utilized for the delivery of many drugs, including various proteins that have, until now, necessitated injections or intravenous infusions.\u003C/p\u003E\n\n\u003Cp\u003EAlliqua intends to capitalize on its technology\u2019s other intrinsic benefits in various market verticals in the healthcare industry, including: wound healing, medical diagnostics and cosmeceuticals.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       44],
      "assets/images/resized/0026/7889/267889v1-max-150x150.png"],
     [[250,
       74],
      "assets/images/resized/0026/7889/267889v1-max-250x250.png"],
     [[348,
       104],
      "assets/images/resized/0026/7889/267889v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$812k",
 "funding_rounds":
  [{"round_code": "partial",
    "source_url": "http://www.sec.gov/Archives/edgar/data/1054274/000105427413000003/xslFormDX01/primary_doc.xml",
    "source_description": "SEC",
    "raised_amount": 812000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 5,
    "funded_day": 7,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "850 THIRD AVENUE",
    "address2": "SUITE 1801",
    "zip_code": "10022",
    "city": "NEW YORK",
    "state_code": "NY",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        112],
       "assets/images/resized/0026/7888/267888v1-max-150x150.png"],
      [[250,
        186],
       "assets/images/resized/0026/7888/267888v1-max-250x250.png"],
      [[450,
        336],
       "assets/images/resized/0026/7888/267888v1-max-450x450.png"]],
    "attribution": null}],
 "external_links":
  []}